These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29616703)

  • 1. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
    J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
    Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
    J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.
    Aisen PS; Bateman RJ; Carrillo M; Doody R; Johnson K; Sims JR; Sperling R; Vellas B
    J Prev Alzheimers Dis; 2021; 8(3):306-312. PubMed ID: 34101788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.
    Angioni D; Cummings J; Lansdall CJ; Middleton L; Sampaio C; Gauthier S; Cohen S; Petersen RC; Rentz DM; Wessels AM; Hendrix SB; Jessen F; Carrillo MC; Doody RS; Irizarry M; Andrews JS; Vellas B; Aisen P
    J Prev Alzheimers Dis; 2024; 11(5):1219-1227. PubMed ID: 39350367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.
    Bateman RJ; Blennow K; Doody R; Hendrix S; Lovestone S; Salloway S; Schindler R; Weiner M; Zetterberg H; Aisen P; Vellas B
    J Prev Alzheimers Dis; 2019; 6(3):169-173. PubMed ID: 31062827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention trials in Alzheimer's disease: an EU-US task force report.
    Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease.
    Penny LK; Lofthouse R; Arastoo M; Porter A; Palliyil S; Harrington CR; Wischik CM
    Transl Neurodegener; 2024 May; 13(1):25. PubMed ID: 38773569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.
    Aisen P; Touchon J; Amariglio R; Andrieu S; Bateman R; Breitner J; Donohue M; Dunn B; Doody R; Fox N; Gauthier S; Grundman M; Hendrix S; Ho C; Isaac M; Raman R; Rosenberg P; Schindler R; Schneider L; Sperling R; Tariot P; Welsh-Bohmer K; Weiner M; Vellas B
    J Prev Alzheimers Dis; 2017; 4(2):116-124. PubMed ID: 29186281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.
    Angioni D; Delrieu J; Hansson O; Fillit H; Aisen P; Cummings J; Sims JR; Braunstein JB; Sabbagh M; Bittner T; Pontecorvo M; Bozeat S; Dage JL; Largent E; Mattke S; Correa O; Gutierrez Robledo LM; Baldivieso V; Willis DR; Atri A; Bateman RJ; Ousset PJ; Vellas B; Weiner M
    J Prev Alzheimers Dis; 2022; 9(4):569-579. PubMed ID: 36281661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.
    Cummings J
    Alzheimers Dement; 2019 Jan; 15(1):172-178. PubMed ID: 29936146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease modification and Neuroprotection in neurodegenerative disorders.
    Cummings J
    Transl Neurodegener; 2017; 6():25. PubMed ID: 29021896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.
    Aisen PS; Siemers E; Michelson D; Salloway S; Sampaio C; Carrillo MC; Sperling R; Doody R; Scheltens P; Bateman R; Weiner M; Vellas B
    J Prev Alzheimers Dis; 2018; 5(3):171-174. PubMed ID: 29972209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining Disease Modifying Therapy for Alzheimer's Disease.
    Cummings J; Fox N
    J Prev Alzheimers Dis; 2017; 4(2):109-115. PubMed ID: 29071250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.